Cargando…
1635. Oral Delivery of Amikacin-Lipid NanoCrystal Formulations Safely and Effectively Treat Macrolide Resistant Mycobacteria Infections in a Mouse Model of Cystic Fibrosis
BACKGROUND: In the cystic fibrosis lung, infections by intracellular pathogens, such as Mycobacteria, are problematic to treat due to a thick buildup of mucous as well as the difficulty of many anti-microbial agents, such as amikacin, to penetrate across the plasma membranes of infected cells. Lipid...
Autores principales: | Lu, Ruying, Mannino, Raphael J, Ordway, Diane J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778159/ http://dx.doi.org/10.1093/ofid/ofaa439.1815 |
Ejemplares similares
-
Amikacin exposure and susceptibility of macrolide-resistant Mycobacterium abscessus
por: Daniel-Wayman, Shelby, et al.
Publicado: (2019) -
1635. Analysis of Antibiotic-Related Malpractice Claims, 2007 to 2016
por: Kabbani, Sarah, et al.
Publicado: (2019) -
Association of NKAPL rs1635 With Cognitive Function in Early-Onset Schizophrenia
por: Yang, Yang, et al.
Publicado: (2022) -
Positive Effect of Liposomal Amikacin for Inhalation on Mycobacterium abcessus in Cystic Fibrosis Patients
por: Caimmi, Davide, et al.
Publicado: (2018) -
Non-Tuberculous Mycobacteria Interference with BCG-Current Controversies and Future Directions
por: Verma, Deepshikha, et al.
Publicado: (2020)